FDA Approves Esaote's Magnifico Open MRI System

Article

The new whole-body magnetic resonance imaging (MRI) platform reportedly offers enhanced image quality and increased patient comfort.

Offering an array of advanced technologies, a newly FDA-approved magnetic resonance imaging (MRI) system may provide radiologists benefits across a variety of clinical applications.

Esaote North America said the Magnifico Open MRI device features metal artifact reduction (MAR), which can facilitate postoperative imaging for patients with metal implants. The system reportedly has a low level of susceptibility for metal in comparison to traditional MRI platforms, according to the company.

When it comes to sports-related injuries, Esaote North America noted the Magnifico Open MRI also has a “True-Motion” feature that allows for real-time imaging of a joint, according to the manufacturer.

In terms of image quality, the company said the Magnifico Open MRI has a high signal-to-noise ratio (SNR) and signal homogeneity that facilitate high spatial resolution.

Emphasizing patient comfort, the open platform may ease anxiety for children and patients with claustrophobia. Esoate North American also noted the device has a transparent head coil and laser alignment that enhance patient comfort and positioning.

“The Magnifico™ Open MRI is designed for patient comfort,” said Stephen Gibbs, the manager of MRI sales and marketing for Esaote North America. “With an open-gantry design, it is ideal for imaging children, large and claustrophobic patients. The compact size is uniquely suited for hospitals, imaging centers, and in-office clinics.”

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
 What New Research Reveals About Portable Low-Field MRI and Patients with Suspected Alzheimer’s Disease
Diagnostic Imaging's Weekly Scan: August 11 — August 17 (Video Version)
Can Portable Low-Field MRI Facilitate Viable Triage and Health Equity for Patients with Suspected Alzheimer’s Disease?
© 2025 MJH Life Sciences

All rights reserved.